Allison M Booth

TL;DR: Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression‐free survival, and there was no significant difference among the three treatment groups with respect to overall survival.

TL;DR: The most effective initial therapy for older adults with CLL has not yet been established due to the lack of comparison of chemoimmunotherapy (CIT) and targeted therapy with the Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib; as part of a randomized phase 3 trial, the Alliance sought to answer these important clinical questions.

TL;DR: In this article, the authors introduced the AE burden score (AEsc) to compare AEs, calculated for each patient by summing over products of reporting period length and grade for each all-cause grade 1-4 AE and dividing by the length of time over which AEs are assessed.

TL;DR: This study compares PFS between IO and IVO using the strategy of response-dependent discontinuation and compares ibrutinib plus venetoclax plus obinutuzumab (IVO) with a response- dependent discontinuation in patients with previously untreated CLL.

TL;DR: In this paper, a prospective trial-based economic analysis of Canadian patients to study the direct medical costs and quality-adjusted benefit associated with ibrutinib-based therapy compared to chemoimmunotherapy with bendamustine-rituximab (BR) was performed.